Tessera Defense & Homeland Security Inc. (HLSQ) company profile
Close on Nov 9, 2026Market cap $2.94MP/E –Yield –
About Tessera Defense & Homeland Security
Services-Prepackaged Software, SIC 7372
BiomX Inc. is a clinical-stage biotechnology company that develops therapies using natural and synthetic bacteriophage technologies. Its phage treatments are engineered to target and eliminate specific pathogenic bacteria associated with chronic medical conditions, particularly diabetic foot infections. The company's pipeline includes fixed multi-phage cocktails such as BX011 and personalized phage approaches like BX211, both designed to combat Staphylococcus aureus infections. These therapeutic candidates serve patient populations suffering from diabetic foot ulcers and diabetic foot osteomyelitis, offering alternatives or complements to conventional antibiotic regimens.
The company maintains its principal executive offices in Dover, Delaware, and holds Delaware corporate registration. Historically, core operations and personnel were situated in Israel through its subsidiary, BiomX Ltd., which entered insolvency proceedings. BiomX has concentrated its clinical and preclinical studies on bacterial targets across the United States and international markets, while also collaborating with entities such as the U.S. Defense Health Agency and the National Institutes of Health.
Summary of the business section of Tessera Defense & Homeland Security's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tessera Defense & Homeland Security Inc.
- Headquarters
- Dover, DE
- Address
- 850 New Burton Road, Suite 201 19904
- Phone
- 972 545610935
- Employees
- 20, Dec 31, 2025
- Industry
- Services-Prepackaged Software
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- HLSQ
- Former tickers
- PHGE until Sep 15, 2026; CHAC until Aug 16, 2021
- Exchange
- OTC
- IPO date
- Dec 14, 2018
- Shares outstanding
- 27M, Aug 18, 2026
- Public float
- $11.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Sep 9, 2026; 1-for-17.33 reverse, Feb 19, 2026; 1-for-19 reverse, Nov 25, 2025; 1-for-10 reverse, Aug 26, 2024
- SEC CIK
- 1739174
- CUSIP
- 09090D608
- ISIN
- US09090D6085
- FIGI
- BBG00MNX7SQ6
- Share class FIGI
- BBG00MNX7SR5
- EIN
- 82-3364020
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan Eitan Solomon | Chief Executive Officer, Director | 126,748 |
| Merav Bassan | Chief Development Officer | 79,597 |
| Marina Wolfson | Chief Financial Officer | 68,545 |
| Reuven Yeganeh | Director | 0 |
| Liat Cohavi Bidas | Director | – |
| James E. Flynn | Director | – |
| Deerfield Healthcare Innovations Fund II, L.P. | Director | – |
| Deerfield Mgmt V, L.P. | Director | – |
| Deerfield Private Design Fund V, L.P. | Director | – |
| Deerfield Mgmt HIF, L.P. | Director | 17,876,098 |
| Deerfield Management Company, L.P. | Director | 2,494,108 |
| Russell Greig | Director | 3,750 |
| Jonathan S. Leff | Director | – |
| Eddie Williams | Director | – |
| Jesse Goodman | Director | – |
| Susan Blum | Director | – |
| Alan Charles Moses | Director | 5,000 |
| Gregory Louis Merril | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $1.08M | $811.28K | $442.27K | $5 | – |
| FY2023 | $1.12M | $839.57K | $509.59K | $12 | – |
| FY2022 | $1.04M | $329.66K | $479.60K | $18 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jonathan Solomon Chief Executive Officer | $453.32K | $70.73K | $639.34K | $211.64K | $1.38M | +27% |
| Marina Wolfson Chief Financial Officer | $249.10K | $38.25K | $164.77K | $101.34K | $553.45K | +57% |
| Dr. Merav Bassan Chief Development Officer | $285.01K | $44.42K | $165.61K | $147.30K | $642.33K | +21% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Dec 14, 2018
- Offer price
- $10.00
- Securities offered
- 7,000,000
- Gross proceeds
- $70.00M
- Exchange
- NYSE American
- First trading day
- Mar 13, 2019
- Lock-up ends (est.)
- Sep 9, 2019
“We are offering 7,000,000 units at an offering price of $10.00 per unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 20 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?